Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Review

DEL in China: the D antigen among serologic RhD-negative individuals

Authors: Qinan Yin, Willy Albert Flegel

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Providing RhD-negative red cell transfusions is a challenge in East Asia, represented by China, Korea, and Japan, where the frequency of RhD-negative is the lowest in the world.

Findings

Among 56 ethnic groups in China, the RhD-negative frequency in Han, the prevalent ethnicity, is 0.5% or less, similar to most other ethnic groups. The Uyghur ethnic group has the highest reported RhD-negative frequency of up to 4.7%, as compared to 13.9% in the US. However, an estimated 7.15 million RhD-negative people live in China. The RhD-negative phenotype typically results from a loss of the entire RHD gene, causing the lack of the RhD protein and D antigen. The DEL phenotype carries a low amount of the D antigen and types as RhD-negative in routine serology. The DEL prevalence in RhD-negative individuals averages 23.3% in the Han, 17% in the Hui and 2.4% in the Uyghur ethnicities. The Asian type DEL, also known as RHD*DEL1 and RHD:c.1227G > A allele, is by far the most prevalent among the 13 DEL alleles observed in China.

Conclusion

The purpose of this review is to summarize the data on DEL and to provide a basis for practical strategy decisions in managing patients and donors with DEL alleles in East Asia using molecular assays.
Literature
1.
Gu J, Sun AY, Wang XD, Shao CP, Li Z, Huang LH, et al. Analysis of density and epitopes of D antigen on the surface of erythrocytes from DEL phenotypic individuals carrying the RHD1227A allele. Blood Transfus. 2014;12:244–9.PubMedPubMedCentral
2.
Klein HG, Anstee DJ. The Rh blood group system (Including LW and RHAG): In: Mollison’s Blood Transfusion in Clinical Medicine, 12th Edn. 2014:170.
3.
4.
Yi CL, Chow YC, Liu YM. The distribution of the Rh factor among Chinese. Sci Technol China. 1949;2:10.PubMed
5.
Wang KY, Liu JS, Chu SY. The distribution of Rh factor among Chinese school girls in Taiwan. Selected Papers of Nat. Defense Med. Center, Taipei, Taiwan. 1956.
6.
de Almeida A. Subsídio para o estudo do factor Rh em Macaenses. Trab Soc portug Abtrop Etnol. 1959;17:445–9.
7.
Grimmo AEP, Lee S-K. A survey of blood groups in Hong Kong Chinese of Cantonese Origin. 1961;31:222–226.
8.
9.
10.
Luettringhaus TA, Cho D, Ryang DW, Flegel WA. An easy RHD genotyping strategy for D-East Asian persons applied to Korean blood donors. Transfusion. 2006;46:2128–37.PubMedCrossRef
11.
Flegel WA. Response to: are weak D RBCs really immunogenic? Transfusion. 2006;46:1063–4.CrossRef
12.
Flegel WA, von Zabern I, Wagner FF. Six years’ experience performing RHD genotyping to confirm D-red blood cell units in Germany for preventing anti-D immunizations. Transfusion. 2009;49:465–71.PubMedCrossRef
13.
14.
Nuchnoi P, Thongbus J, Srisarin A, Kerdpin U, Prachayasittikul V. Clinical and laboratory update on the DEL variant. Lab Med. 2014;45:285–90.PubMedCrossRef
15.
16.
National Bureau of Statistics of China. Ethnic groups recognized by the People’s Republic of China. Wikipedia. 2020.
17.
Shao CP, Maas JH, Su YQ, Kohler M, Legler TJ. Molecular background of Rh D-positive, D-negative, D(el) and weak D phenotypes in Chinese. Vox Sang. 2002;83:156–61.PubMedCrossRef
18.
Chen Q, Li M, Li M, Lu XS, Lu R, Sun J, et al. Molecular basis of weak D and DEL in Han population in Anhui Province, China. Chin Med J (Engl). 2012;125:3251–5.
19.
Liu J, Zhang S, Wang Q, Shen H, Zhang Y, Liu M. Frequencies and ethnic distribution of ABO and RhD blood groups in China: a population-based cross-sectional study. BMJ Open. 2017;7:e018476.PubMedPubMedCentralCrossRef
20.
Li Q, Ye LY, Guo ZH, Zhang YX, Wang LL, Zhu ZY. Molecular basis of D variants between Uigur and Han blood donors in Xinjiang. Transfus Med. 2008;18:199–203.PubMedCrossRef
21.
Kurexijiang T, Hamulati W, Nuermaimaiti Y, Muyasaier K, Palida Habaer R, Halike Y, et al. Comparative investigation of the Rh blood type distribution between the Uygur and Han nationalities in the Khotan area of Xinjiang Autonomous Region. Di Yi Jun Yi Da Xue Xue Bao. 2004;24:447–9.PubMed
22.
Zhou Y. Significance of detection of Rh System D, C, and E antigens in transfusion compatibility of Tibetan. Labeled Immunoassays Clin Med. 2018;25:1842–4.
23.
Pan QR, Zhong J, Yang Y, Yu F, Zhou Q, Zhong CL. The investigation and analysis of the Rh blood type distribution in four kinds of the minority nationalities (Miao, Buyi, Dong and Shui) in Guizhou, China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006;23:571–3.PubMed
24.
25.
National Bureau of Statistics of China. The 6th National Population Census of the People’s Republic of China. Wikipedia. 2020.
26.
Gao Y, Zhang C, Yuan L, Ling Y, Wang X, Liu C, et al. PGG. Han: the Han Chinese genome database and analysis platform. Nucleic Acids Res. 2020;48:D971–6.PubMedCrossRef
27.
Joniak-Lüthi A. The Han: China’s diverse majority. Seattle: University of Washington Press; 2015.
28.
Li Q, Hou L, Guo ZH, Ye LY, Yue DQ, Zhu ZY. Molecular basis of the RHD gene in blood donors with DEL phenotypes in Shanghai. Vox Sang. 2009;97:139–46.PubMedCrossRef
29.
30.
Xu W, Zhu M, Wang BL, Su H, Wang M. Prospective evaluation of a transfusion policy of RhD-positive red blood cells into DEL patients in China. Transfus Med Hemother. 2015;42:15–21.PubMedCrossRef
31.
Bie LL, Ma HW, Chen Z, Zhang BW. Analysis on del detection of RhD (−) in unrelated blood donors. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:1071–3.PubMed
32.
Wu X, Wu D, Wang M, Shao C, Xu H. Analysis of frequency of a RHD1227A allele in Chinese Hans. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014;31:793–6.PubMed
33.
Ye SH, Wu DZ, Wang MN, Wu XY, Xu HG, Xu H, et al. A comprehensive investigation of RHD polymorphisms in the Chinese Han population in Xi’an. Blood Transfus. 2014;12:396–404.PubMedPubMedCentral
34.
Mak KH, Yan KF, Cheng SS, Yuen MY. Rh phenotypes of Chinese blood donors in Hong Kong, with special reference to weak D antigens. Transfusion. 1993;33:348–51.PubMedCrossRef
35.
36.
Wagner FF, Moulds JM, Flegel WA. Genetic mechanisms of Rhesus box variation. Transfusion. 2005;45:338–44.PubMedCrossRef
37.
Zhu ZY. Molecular background of the rare blood in Chinese population. 2008;3:205–207.
38.
Ito S, Ohto H, Ogiyama Y, Irino M, Omokawa S, Shibasaki I, et al. A practical and effective strategy in East Asia to prevent anti-D alloimmunization in patients by C/c phenotyping of serologic RhD-negative blood donors. eJHaem. 2021;1 (in press).
39.
Li Q, Ye LY, Guo ZH, Qian M, Zhu ZY. Study on the molecular background of Del phenotype in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006;23:486–91.PubMed
40.
Xu Q, Grootkerk-Tax MG, Maaskant-van Wijk PA, van der Schoot CE. Systemic analysis and zygosity determination of the RHD gene in a D-negative Chinese Han population reveals a novel D-negative RHD gene. Vox Sang. 2005;88:35–40.PubMedCrossRef
41.
Li JH, Zhang CY, Sun JH. Molecular mechanism of RhDel phenotype in blood donation population of Chinese Harbin area. Liu J Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20:1478–81.PubMed
42.
Wang QP, Dong GT, Wang XD, Gu J, Li Z, Sun AY, et al. An investigation of secondary anti-D immunisation among phenotypically RhD-negative individuals in the Chinese population. Blood Transfus. 2014;12:238–43.PubMedPubMedCentral
43.
Wang M, Wang BL, Xu W, Fan DD, Peng ML, Pan J, et al. Anti-D alloimmunisation in pregnant women with DEL phenotype in China. Transfus Med. 2015;25:163–9.PubMedCrossRef
44.
Wang YH, Chen JC, Lin KT, Lee YJ, Yang YF, Lin TM. Detection of RhD(el) in RhD-negative persons in clinical laboratory. J Lab Clin Med. 2005;146:321–5.PubMedCrossRef
45.
Chen JC, Lin TM, Chen YL, Wang YH, Jin YT, Yue CT. RHD 1227A is an important genetic marker for RhD(el) individuals. Am J Clin Pathol. 2004;122:193–8.PubMedCrossRef
46.
Sun CF, Chou CS, Lai NC, Wang WT. RHD gene polymorphisms among RhD-negative Chinese in Taiwan. Vox Sang. 1998;75:52–7.PubMedCrossRef
47.
Sun CF, Liu JP, Chen DP, Wang WT, Yang TT. Use of real time PCR for rapid detection of Del phenotype in Taiwan. Ann Clin Lab Sci. 2008;38:258–63.PubMed
48.
Flegel WA, Wagner FF, Donghaile PO. Anti-D immunization rates may exceed 50% in many clinically relevant settings, despite varying widely among patient cohorts. Transfusion. 2020;60:1109–10.PubMedCrossRefPubMedCentral
49.
Shao CP. Transfusion of RhD-positive blood in “Asia type” DEL recipients. N Engl J Med. 2010;362:472–3.PubMedCrossRef
50.
Wei Q. Random survey for RH allele polymorphism among 50 native Tibetans [Dissertation]. Ulm: Universität Ulm; 2006.
51.
Chen Q. Random survey for RHD alleles among D positive Europeans. [Dissertation]. Universität Ulm, Ulm. 2004.
52.
Chen Q, Flegel WA. Random survey for RHD alleles among D+ European persons. Transfusion. 2005;45:1183–91.PubMedCrossRef
53.
Yu X, Wagner FF, Witter B, Flegel WA. Outliers in RhD membrane integration are explained by variant RH haplotypes. Transfusion. 2006;46:1343–51.PubMedCrossRef
54.
Kim JY, Kim SY, Kim CA, Yon GS, Park SS. Molecular characterization of D- Korean persons: development of a diagnostic strategy. Transfusion. 2005;45:345–52.PubMedCrossRef
55.
Gassner C, Doescher A, Drnovsek TD, Rozman P, Eicher NI, Legler TJ, et al. Presence of RHD in serologically D−, C/E+ individuals: a European multicenter study. Transfusion. 2005;45:527–38.PubMedCrossRef
56.
Orzinska A, Guz K, Polin H, Pelc-Klopotowska M, Bednarz J, Gielezynska A, et al. RHD variants in Polish blood donors routinely typed as D. Transfusion. 2013;53:2945–53.PubMedPubMedCentral
57.
Moussa H, Tsochandaridis M, Chakroun T, Jridi S, Abdelneji B, Hmida S, et al. Molecular background of D-negative phenotype in the Tunisian population. Transfus Med. 2012;22:192–8.PubMedCrossRef
58.
Silvy M, Chapel-Fernandes S, Callebaut I, Beley S, Durousseau C, Simon S, et al. Characterization of novel RHD alleles: relationship between phenotype, genotype, and trimeric architecture. Transfusion. 2012;52:2020–9.PubMedCrossRef
59.
Chang J-G, Wang J-C, Yang T-Y, Tsan K-W, Shih M-C, Peng C-T, et al. Human RhDel is caused by a deletion of 1,013 bp between introns 8 and 9 including exon 9 of RHD gene. Blood. 1998;92:2602–4.PubMedCrossRef
60.
Peng CT, Shih MC, Liu TC, Lin IL, Jaung SJ, Chang JG. Molecular basis for the RhD negative phenotype in Chinese. Int J Mol Med. 2003;11:515–21.PubMed
61.
Kormoczi GF, Gassner C, Shao CP, Uchikawa M, Legler TJ. A comprehensive analysis of DEL types: partial DEL individuals are prone to anti-D alloimmunization. Transfusion. 2005;45:1561–7.PubMedCrossRef
62.
Salmon C, Cartron JP, Rouger P. The human blood groups. New York: Masson; 1984. p. 220.
63.
Issitt PD, Telen MJ. Introduction of the term “partial D.” Transfusion. 1996;36:761–2.CrossRef
64.
Shao CP, Xu H, Xu Q, Sun GD, Li JP, Zhang BW, et al. Antenatal Rh prophylaxis is unnecessary for “Asia type” DEL women. Transfus Clin Biol. 2010;17:260–4.PubMedCrossRef
65.
Kim H, Ko DH. Reconsidering RhD positive blood transfusion for Asia type DEL patients. Transfus Apher Sci. 2019;58:422.PubMedCrossRef
66.
Wagner T, Kormoczi GF, Buchta C, Vadon M, Lanzer G, Mayr WR, et al. Anti-D immunization by DEL red blood cells. Transfusion. 2005;45:520–6.PubMedCrossRef
67.
Yasuda H, Ohto H, Sakuma S, Ishikawa Y. Secondary anti-D immunization by Del red blood cells. Transfusion. 2005;45:1581–4.PubMedCrossRef
68.
Kim KH, Kim KE, Woo KS, Han JY, Kim JM, Park KU. Primary anti-D immunization by DEL red blood cells. Korean J Lab Med. 2009;29:361–5.PubMed
69.
Chen Q, Liu Z. Retrospective analysis of transfusion DEL blood to RhD-negative recipients. Transfusion. 2012;52(Supplement):36A.
70.
Crottet SL, Henny C, Meyer S, Still F, Stolz M, Gottschalk J, et al. Implementation of a mandatory donor RHD screening in Switzerland. Transfus Apher Sci. 2014;50:169–74.PubMedCrossRef
71.
Flegel WA, Gabriel C, Gassner W, Ruff H, Wagner FF. RHD genotyping of blood donors may avoid Anti-D immunization. Blood. 2004;104:2706.CrossRef
72.
Srivastava K, Stiles DA, Wagner FF, Flegel WA. Two large deletions extending beyond either end of the RHD gene and their red cell phenotypes. J Hum Genet. 2018;63:27–35.PubMedCrossRef
73.
Mota M, Dezan M, Valgueiro MC, Sakashita AM, Kutner JM, Castilho L. RHD allelic identification among D-Brazilian blood donors as a routine test using pools of DNA. J Clin Lab Anal. 2012;26:104–8.PubMedPubMedCentralCrossRef
74.
WHO. Global Status Report on Blood Safety and Availability, 2016. World Health Organization, 2017.
75.
Zhuang JM, Huang J, Tan CR, Zhang JR, Tang LZ, Chen Y, et al. Statistic standardization and clinical application of the objetive indicators for evaluating clinical blood transfusion in general medical institutions (in Chinese). Zhong Guo Shu Xue Za Zhi. 2014;27:50–2.
76.
National Bureau of Statistics of China. Study on measurement of population changes with implementation of a comprehensive two-child policy. 2019. http://​en.​nhc.​gov.​cn/​. Accessed 15 July 2020.
77.
An W. A survey on voluntary non-remunerated donation among 355 blood centers in China between 2006–2008. Zhong Guo Shu Xue Za Zhi. 2010;23(suppl):22.
78.
79.
Ming M. China sees growth in voluntary blood donations for over 20 consecutive years Xinhua. 2019.
80.
Seltsam A, Wagner FF, Salama A, Flegel WA. Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion. 2003;43:1563–6.PubMedCrossRef
81.
Sandler SG, Flegel WA, Westhoff CM, Denomme GA, Delaney M, Keller MA, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion. 2015;55:680–9.PubMedCrossRef
82.
Ni D. Drugs for pregnant women with rare blood type seized by customs. Sixth Tone. 2017.
83.
Ni D. China’s Rh-negative expectant moms still rely on smuggled drugs. Sixth Tone. 2018.
84.
Kacker S, Vassallo R, Keller MA, Westhoff CM, Frick KD, Sandler SG, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion. 2015;55:2095–103.PubMedPubMedCentralCrossRef
85.
Flegel WA, Denomme GA, Queenan JT, Johnson ST, Keller MA, Westhoff CM, et al. It’s time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4. Transfusion. 2020;60:855–9.PubMedCrossRefPubMedCentral
86.
Flegel WA, Castilho L, Delaney M, Klapper EB, Moulds JM, Noizat-Pirenne F, et al. Molecular immunohaematology round table discussions at the AABB Annual Meeting, Denver 2013. Blood Transfus. 2015;13:514–20.PubMedPubMedCentral
87.
Avent ND. Molecular genetic methods: principles and feasibility in transfusion medicine. Vox Sang. 1998;74(Suppl 2):275–84.PubMedCrossRef
88.
Flegel WA, Wagner FF, Muller TH, Gassner C. Rh phenotype prediction by DNA typing and its application to practice. Transfus Med. 1998;8:281–302.PubMedCrossRef
89.
90.
91.
92.
Denomme GA, Flegel WA. Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion. 2008;48:2461–75.PubMedCrossRef
93.
94.
Denomme GA, Anani WQ, Avent ND, Bein G, Briggs LB, Lapadat RC, et al. Red cell genotyping precision medicine: a conference summary. Ther Adv Hematol. 2017;8:277–91.PubMedPubMedCentralCrossRef
95.
96.
97.
Flegel WA, Gottschall JL, Denomme GA. Integration of red cell genotyping into the blood supply chain: a population-based study. Lancet Haematol. 2015;2:e282–9.PubMedPubMedCentralCrossRef
98.
99.
Bennett PR, Le Van KC, Colin Y, Warwick RM, Cherif-Zahar B, Fisk NM, et al. Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med. 1993;329:607–10.PubMedCrossRef
100.
Simsek S, Bleeker PM, von dem Borne AE. Prenatal determination of fetal RhD type. N Engl J Med. 1994;330:795–6.PubMedCrossRef
101.
Wu JJ, Hong XZ, Xu XG, Ma KR, Zhu FM, Yan LX. RHD 1227A allele frequency among Rh negative population and random population. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14:1234–7.PubMed
102.
Shao CP, Wang BY, Ye SH, Zhang WL, Xu H, Zhuang NB, et al. DEL RBC transfusion should be avoided in particular blood recipient in East Asia due to allosensitization and ineffectiveness. J Zhejiang Univ Sci B. 2012;13:913–8.PubMedPubMedCentralCrossRef
103.
Ogasawara K, Suzuki Y, Sasaki K, Osabe T, Isa K, Tsuneyama H, et al. Molecular basis for D- Japanese: identification of novel DEL and D- alleles. Vox Sang. 2015;109:359–65.PubMedCrossRef
104.
Kim B, Lee ST, Kim S, Choi JR, Kim HO. Application of multiplex ligation-dependent probe amplification assay for genotyping major blood group systems including DEL variants in the D-Negative Korean Population. Ann Lab Med. 2018;38:32–8.PubMedCrossRef
105.
Thongbut J, Raud L, Ferec C, Promwong C, Nuchnoi P, Fichou Y. Comprehensive molecular analysis of serologically D-Negative and weak/partial D phenotype in thai blood donors. Transfus Med Hemother. 2020;47:54–60.PubMedCrossRef
106.
Kim TY, Hong YJ, Kim MJ, Kim H, Kim TS, Park JS, et al. Recommendations regarding practical DEL typing strategies for serologically D-negative Asian donors. Transfus Med Hemother. 2020;47:88–93.PubMedCrossRef
107.
Metadata
Title
DEL in China: the D antigen among serologic RhD-negative individuals
Authors
Qinan Yin
Willy Albert Flegel
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03116-6

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue

Research

Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients

Research

Gene profiling of Toll-like receptor signalling pathways in neutrophils of patients with acute-on-chronic liver failure

Review

Translational stem cell therapy: vascularized skin grafts in skin repair and regeneration

Research

Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia

Letter to the Editor

Seasonal rhythms of vasopressin release and aquaporin-2 excretion assure appropriate water conservation in humans

Research

The gut microbiota is associated with the small intestinal paracellular permeability and the development of the immune system in healthy children during the first two years of life
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits